NCT05961384 is a Phase 1 clinical trial of baxdrostat in Hypertension, sponsored by AstraZeneca.

Who is sponsoring NCT05961384?

NCT05961384 is sponsored by AstraZeneca.

What drugs are being tested in NCT05961384?

Interventions in NCT05961384: baxdrostat.

What condition does NCT05961384 study?

NCT05961384 studies Hypertension.

Is NCT05961384 still recruiting?

NCT05961384 is currently completed. Last updated 15 August 2023.

Last reviewed 2023-08-15 · How we verify

NCT05961384

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat

Completed Phase 1 Last updated 15 August 2023

What this trial tests

Phase 1 trial testing baxdrostat in Hypertension in 8 participants. Completed in 15 January 2022.

Timeline

18 November 2021

Primary endpoint
15 January 2022

15 January 2022

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	18 November 2021
Primary completion	15 January 2022
Estimated completion	15 January 2022
Sites	1 location across United States

Drugs / interventions tested

baxdrostat — full drug profile →

Conditions studied

Hypertension — all drugs for Hypertension →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 55, male only, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This was a Phase 1, open-label, single dose study in healthy male subjects. The goals of this clinical trial were to determine how baxdrostat might be absorbed and metabolized using radioactive \[14C\] labeled baxdrostat. Subjects were administered a single oral dose of 10 mg containing approximately 100 μCi of \[14C\] baxdrostat. Subjects were to be confined to the study site for 9 to 15 days for blood, urine, and feces collections.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of baxdrostat

Trials testing the same drug.

NCT05966324 — Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population · Phase 1 · completed
NCT05961397 — Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic Impairment · Phase 1 · completed

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05961384 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 15 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05961384.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing